# Resistant Hypertension Optimal Treatment

> **NCT01643434** · PHASE4 · UNKNOWN · sponsor: **Instituto do Coracao** · enrollment: 2000 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Clonidine

## Key facts

- **NCT ID:** NCT01643434
- **Lead sponsor:** Instituto do Coracao
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2013-12
- **Final completion:** 2014-07
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2013-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01643434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01643434, "Resistant Hypertension Optimal Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01643434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*